Compare FLY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | PTGX |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | 1409 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.5B |
| IPO Year | N/A | 2016 |
| Metric | FLY | PTGX |
|---|---|---|
| Price | $18.92 | $131.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $38.88 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 4.9M | 761.7K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $174.79 | $874.25 |
| Revenue Next Year | $66.73 | N/A |
| P/E Ratio | ★ N/A | $2,730.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.00 | $50.49 |
| 52 Week High | $62.17 | $141.10 |
| Indicator | FLY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 28.00 | 60.69 |
| Support Level | $18.07 | $94.48 |
| Resistance Level | $21.93 | $141.10 |
| Average True Range (ATR) | 2.02 | 6.14 |
| MACD | -0.41 | -0.37 |
| Stochastic Oscillator | 1.22 | 58.96 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.